Immunophenotypic Evolution and Clinical Outcomes in R/R AML Treated with Revumenib
Posted inHematology-Oncology news Pathology & Lab Medicine/Bệnh học

Immunophenotypic Evolution and Clinical Outcomes in R/R AML Treated with Revumenib

A study of 48 patients with R/R AML treated with revumenib revealed that 52% experienced dynamic immunophenotypic changes. Achieving MRD-negative morphologic remission significantly improved overall survival, highlighting the necessity for specialized flow cytometry monitoring during menin inhibitor therapy.
From Pressure to Cancer: Unveiling the Integrin αV-YAP-CTGF Axis as a Therapeutic Target in Congestive Hepatopathy
Posted inCardiology Gastroenterology news

From Pressure to Cancer: Unveiling the Integrin αV-YAP-CTGF Axis as a Therapeutic Target in Congestive Hepatopathy

Researchers have identified a novel signaling pathway in liver sinusoidal endothelial cells (LSECs) that drives fibrosis and liver cancer in congestive hepatopathy. The study highlights the Integrin αV-YAP-CTGF axis as a critical mechanism and potential therapeutic target for patients with chronic hepatic congestion.
Nerandomilast Shows Potential Mortality Benefit in IPF Despite Neutral Composite Secondary Endpoints: Insights from FIBRONEER-IPF Extended Follow-up
Posted inInternal Medicine news Respiratory

Nerandomilast Shows Potential Mortality Benefit in IPF Despite Neutral Composite Secondary Endpoints: Insights from FIBRONEER-IPF Extended Follow-up

Long-term data from the FIBRONEER-IPF trial indicates that while nerandomilast did not significantly impact composite respiratory events, the 18 mg dose suggests a numerical reduction in mortality and maintains a favorable safety profile for patients with idiopathic pulmonary fibrosis.
Optimizing Influenza Protection in the Aging Diabetic Population: Evidence from the DANFLU-2 High-Dose Vaccine Trial
Posted inClinical Updates Diabetes & Endocrinology news Respiratory

Optimizing Influenza Protection in the Aging Diabetic Population: Evidence from the DANFLU-2 High-Dose Vaccine Trial

This secondary analysis of the DANFLU-2 trial demonstrates that high-dose influenza vaccines provide superior protection against cardiorespiratory and cardiovascular hospitalizations in older adults with diabetes, particularly those with a disease duration exceeding five years.